PRODUCT INFORMATION

Clone ID	1G9
Target	CL2A
Synonyms	N.A.
Host Species	Rabbit
Description	Biotinylated Anti-CL2A(ADC linker) antibody(1G9); Rabbit mAb
Delivery	2-3 weeks
Uniprot ID	N.A.
IgG type	Rabbit IgG
Clonality	Monoclonal
Reactivity	N.A.
Applications	ELISA
Recommended Dilutions	ELISA 1:5000-10000
Purification	Purified from cell culture supernatant by affinity chromatography
Endotoxin	Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μm) prior to use.
Background	CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types.
Usage	Research use only
Conjugate	Biotinylated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scr